Noonan Spectrum Disorders Gene Mutation Panel, NGS
This gene mutation panel is used to identify mutations in a genetically heterogenous group of disorders associated with defects in the RAS/MAPK signaling pathway (RASopathies) termed ‘Noonan spectrum disorders. Clinical features of these disorders include short stature, cardiovascular defects, developmental delays, characteristic facial features, and an increased risk for specific types of cancer. The disorders included on this panel are Noonan syndrome, LEOPARD syndrome, Cardio-facial syndrome, and Costello syndrome.
Noonan syndrome is an autosomal dominantly inherited disease characterized by short stature, congenital heart defects and variably delayed mental development. Patients with Noonan syndrome have a characteristic appearance: short neck, cervical skin fold, low set ears, hypertelorism. Additionally, lymphatic system dysplasia may occur, resulting in cystic hygroma and occipital fold enlargement in the fetus. The incidence of Noonan syndrome is about 1:1000-2500. In 50% of patients the mutations are in the PTPN11 gene, 10-13% are associated with mutations in the SOS1 gene, 5% with mutations in the RAF1 gene and <5% are due to mutations in the KRAS gene.
LEOPARD syndrome is an autosomal dominantly inherited condition characterized by abnormalities of the skin, heart, inner ears, and genitalia. LEOPARD syndrome belongs to a group of related conditions that have overlapping clinical features and are all caused by genetic changes that disrupt the body's RAS pathway, affecting growth and development (‘RASopathies’). The characteristic features of LEOPARD syndrome include brown skin spots called lentigines, heart defects, widely spaced eyes (ocular hypertelorism), a sunken chest (pectus excavatum) or protruding chest (pectus carinatum) and short stature. Approximately 85 percent of individuals with this condition have mutations in the PTPN11 gene. Another 10 percent have mutations in the RAF1 gene. In rare cases, mutations in the BRAF or MAP2K1 gene have been found to cause this condition.
Cardiofaciocutaneous syndrome is a disorder that affect the heart (cardio-), face (facio-), and the skin / hair (cutaneous). Additional features of this disorder in children and adults macrocephaly, short stature, visual problems, and seizures. People with this condition also have delayed development and intellectual disability, usually ranging from moderate to severe. Cardiofaciocutaneous syndrome is considered to be an autosomal dominant condition and can be caused by mutations in several genes. Mutations in BRAF are most common, accounting for 75 to 80 percent of all cases. Another 10 to 15 percent of cases result from mutations in one of two similar genes, MAP2K1 and MAP2K2. Fewer than 5 percent of cases are caused by mutations in the KRAS gene.
Costello syndrome is an autosomal dominant disorder characterized by delayed development and intellectual disability, loose folds of skin (which are especially noticeable on the hands and feet), unusually flexible joints, distinctive facial features (including a large mouth with full lips) and hypertrophic cardiomyopathy. Other signs and symptoms of Costello syndrome can include tight achilles tendons, hypotonia, a characteristic brain malformation where the cerebellar tonsils are long and extend past the foramen magnum (Chiari I malformation) , skeletal abnormalities, dental problems, and problems with vision. The prevalence ranges from 1 in 300,000 to 1 in 1.25 million people. Costello syndrome is caused by mutations in the HRAS gene.
Panel Components Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: A2ML1, ACTB, ACTG1, BRAF, CABIN1, CBL, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, NF1, NF2, NRAS, NSUN2, PPP1CB, PTPN11, RAF1, RASA2, RIT1, RRAS, SHOC2, SOS1, SOS2, SPRED1 associated with Noonan spectrum disorders.
- Diagnostic confirmation of Noonan syndrome, LEOPARD syndrome, Cardiofaciocutaneous syndrome and Costello syndrome
- For a comprehensive genetic evaluation for patients with a personal or family history suggestive of Noonan syndrome (NS) or related disorders
- Prenatal and parental testing in families at risk
- Identifying variants within genes known to be associated with increased risk for disease features allowing for predictive testing of at-risk family members
Negative for mutation or pathogenic variant in the tested genes
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Lancet. 2013;381: 333-42. [PMID: 23312968]
- Proc Natl Acad Sci U S A. 2014;111: 11473-8. [PMID: 25049390]
- BMC Med Genet. 2014 Apr 26;15:44. [PMID: 24767283]
- Annu Rev Genomics Hum Genet. 2013; 14: 355-369 [PMID: 23875798]
- Genet Med. 2012;14: 285-92. [PMID: 22261753]
- Int J Dermatol. 2010;49: 1146-51. [PMID: 20883402]
- Am J Med Genet A. 2007;143A:1472-80. [PMID: 17551924]
- Am J Med Genet A. 2006;140: 8-16. [PMID: 16372351]
- J Med Genet. 2006;43: 833-42. [PMID: 16825433]